Reference Source

Opto-Pharm Pte Ltd. · 66-41 · SINGAPORE

For Opto-Pharm Pte Ltd. · 66-41 · SINGAPORE, import alert is 66-41; import alert name is Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S; country is SINGAPORE; product code is 54 Y - - 99 Vitamin, Mineral, Proteins and Unconventional Dietary Specialities For Humans and Animals, N.E.C. | 66 V - - 99 Miscellaneous Patent Medicines, Etc; date published is 09/30/2009; address is 13 Tuas Avenue 12 , Singapore, SINGAPORE, verified against its source on 2026-09-16.

Firm
Opto-Pharm Pte Ltd. verified
Import alert
66-41
Import alert name
Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S.
Country
SINGAPORE verified
Address
13 Tuas Avenue 12 , Singapore, SINGAPORE verified
Date published
09/30/2009 verified
Product code
54 Y - - 99 Vitamin, Mineral, Proteins and Unconventional Dietary Specialities For Humans and Animals, N.E.C. | 66 V - - 99 Miscellaneous Patent Medicines, Etc. each item verified
FDA notes
Orto eyes is labeled as a dietary supplement and as a protectant against eye irritation or to relieve dryness of the eye. Based on its route of administration (opthamalic); this product does not qualify as a dietary supplement because it is not ingested. In addition; the website www.aor.ca that describes Ortho Eyes product; promotes one of its ingrediants N-acetyl-carnosine to improve eyesite; treat corneal dtsrophy; corneal trophic keratitus and bullous keratopathy. Based on its intended uses this product is a drug. Further; we are not aware of anyth substantial scientific evidence that this product is generally recognized as safe and effective for the conditions recommended or suggested on its labeling. | Ortho eyes is labeled as a dietary supplement and as a protectant against eye irritation or to relieve dryness of the eye. Based on its route of administration (opthamalic); this product does not qualify as a dietary supplement because it is not ingested. In addition; the website www.aor.ca that describes Ortho Eyes product; promotes one of its ingrediants N-acetyl-carnosine to improve eyesite; treat corneal dtsrophy; corneal trophic keratitus and bullous keratopathy. Based on its intended uses this product is a drug. Further; we are not aware of anyth substantial scientific evidence that this product is generally recognized as safe and effective for the conditions recommended or suggested on its labeling. each item verified
Sourceaccessdata.fda.gov
Verified
Review by
DatasetFDA import alert red lists: firms subject to detention without physical examination

What the source says

Opto-Pharm Pte Ltd. Date Published : 09/30/2009 13 Tuas Avenue 12 , Singapore, SINGAPORE 54 Y - - 99 Vitamin, Mineral, Proteins and Unconventional Dietary Specialities For Humans and Animals, N.E.C. Date Published: 09/30/2009 Notes: Orto eyes is labeled as a dietary supplement and as a protectant against eye irritation or to relieve dryness of the eye. Based on its route of administration (opthamalic); this product does not qualify as a dietary supplement because it is not ingested. In addition; the website www.aor.ca that describes Ortho Eyes product; promotes one of its ingrediants N-acetyl-carnosine to improve eyesite; treat corneal dtsrophy; corneal trophic keratitus and bullous keratopathy. Based on its intended uses this product is a drug. Further; we are not aware of anyth substantial scientific evidence that this product is generally recognized as safe and effective for the conditions recommended or suggested on its labeling. 66 V - - 99 Miscellaneous Patent Medicines, Etc. Date Published: 09/30/2009 Notes: Ortho eyes is labeled as a dietary supplement and as a protectant against eye irritation or to relieve dryness of the eye. Based on its route of administration (opthamalic); this product does not qualify as a dietary supplement because it is not ingested. In addition; the website www.aor.ca that describes Ortho Eyes product; promotes one of its ingrediants N-acetyl-carnosine to improve eyesite; treat corneal dtsrophy; corneal trophic keratitus and bullous keratopathy. Based on its intended uses this product is a drug. Further; we are not aware of anyth substantial scientific evidence that this product is generally recognized as safe and effective for the conditions recommended or suggested on its labeling.

accessdata.fda.gov, retrieved 2026-09-15

Source

Last verified against source: . Due for re-check by . This page as Markdown · OKF bundle · full dataset as JSON.

This one changes, and we watch it.FDA import alert red lists: firms subject to detention without physical examination is re-read on a schedule and every change is dated. Subscribe: Atom feed · JSON · what has changed so far.